{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:56:30Z","timestamp":1740149790912,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12328-019-00985-9","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T04:55:27Z","timestamp":1556600127000},"page":"578-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2916-2268","authenticated-orcid":false,"given":"Koichi","family":"Soga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Itani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"985_CR1","first-page":"555","volume":"181","author":"MA Peppercorn","year":"1972","unstructured":"Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. J Pharmacol Exp Ther. 1972;181:555\u201362.","journal-title":"J Pharmacol Exp Ther"},{"key":"985_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/0016-5085(95)90154-X","volume":"108","author":"JB Sturgeon","year":"1995","unstructured":"Sturgeon JB, Bhatia P, Hermens D, et al. Exacerbation of chronic ulcerative colitis with mesalamine. Gastroenterology. 1995;108:1889\u201393.","journal-title":"Gastroenterology"},{"key":"985_CR3","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00384-009-0727-x","volume":"24","author":"A Bousseaden","year":"2009","unstructured":"Bousseaden A, Ajana FZ, Essamri W, et al. Mesalamine enema-induced exacerbation of ulcerative colitis. Int J Colorectal Dis. 2009;24:1359\u201360.","journal-title":"Int J Colorectal Dis"},{"issue":"Suppl 2","key":"985_CR4","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1097\/00054725-200810001-00099","volume":"14","author":"ML Scribano","year":"2008","unstructured":"Scribano ML. Adverse events of IBD therapies. Inflamm Bowel Dis. 2008;14(Suppl 2):S210\u20131.","journal-title":"Inflamm Bowel Dis"},{"key":"985_CR5","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987;317:1625\u20139.","journal-title":"N Engl J Med"},{"key":"985_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/gut.47.3.404","volume":"47","author":"K Geboes","year":"2000","unstructured":"Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404\u20139.","journal-title":"Gut"},{"key":"985_CR7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0889-8553(21)00053-4","volume":"21","author":"H Allgayer","year":"1992","unstructured":"Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol Clin North Am. 1992;21:643\u201358.","journal-title":"Gastroenterol Clin North Am"},{"key":"985_CR8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0016-5085(82)80075-9","volume":"83","author":"SN Rasmussen","year":"1982","unstructured":"Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982;83:1062\u201370.","journal-title":"Gastroenterology"},{"key":"985_CR9","first-page":"893","volume":"3","author":"R Karagozian","year":"2007","unstructured":"Karagozian R, Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag. 2007;3:893\u2013903.","journal-title":"Ther Clin Risk Manag"},{"key":"985_CR10","first-page":"A349","volume":"135","author":"DT Rubin","year":"2009","unstructured":"Rubin DT, Mikolajczyk A, Surma B. Measurement of luminal pH in patients with mildly to moderately active UC: a pilot study using SMARTpill pH. Gastroenterology. 2009;135:A349.","journal-title":"Gastroenterology"},{"key":"985_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/ibd.20049","volume":"13","author":"S Menees","year":"2007","unstructured":"Menees S, Higgins P, Korsnes S, Elta G. Does colonoscopy cause increased ulcerative colitis symptoms? Inflamm Bowel Dis. 2007;13:12\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"985_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.crohns.2007.08.009","volume":"1","author":"D Schleiermacher","year":"2007","unstructured":"Schleiermacher D, Hoffmann JC. Pulmonary abnormalities in inflammatory bowel disease. J Crohns Colitis. 2007;1:61\u20139.","journal-title":"J Crohns Colitis"},{"key":"985_CR13","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/0016-5085(92)91453-B","volume":"103","author":"ML Hautekeete","year":"1992","unstructured":"Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology. 1992;103:1925\u20137.","journal-title":"Gastroenterology"},{"key":"985_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00004836-198812000-00012","volume":"10","author":"JM Fardy","year":"1988","unstructured":"Fardy JM, Lloyd DA, Reynolds RPE. Adverse effects with oral 5-aminosalicylic acid. J Clin Gastroenterol. 1988;10:635\u20137.","journal-title":"J Clin Gastroenterol"},{"key":"985_CR15","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1034\/j.1398-9995.1999.00298.x","volume":"54","author":"MA Gonzalo","year":"1999","unstructured":"Gonzalo MA, Alcalde MM, Garc\u00eda JM, et al. Desensitization after fever induced by mesalazine. Allergy. 1999;54:1224\u20135.","journal-title":"Allergy"},{"key":"985_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1034\/j.1398-9995.2001.1n3420.x","volume":"57","author":"S Varela","year":"2002","unstructured":"Varela S, D\u00edez MS, Gonzalez C, et al. Oral desensitization to 5-ASA. Allergy. 2002;57:371\u20132.","journal-title":"Allergy"},{"key":"985_CR17","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1002\/ibd.21323","volume":"17","author":"P Oustamanolakis","year":"2011","unstructured":"Oustamanolakis P, Koutroubakis IE. New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. Inflamm Bowel Dis. 2011;17:E8\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"985_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00004836-198404000-00005","volume":"6","author":"BI Korelitz","year":"1984","unstructured":"Korelitz BI, Present DH, Rubin PH, et al. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. J Clin Gastroenterol. 1984;6:27\u201331.","journal-title":"J Clin Gastroenterol"},{"key":"985_CR19","first-page":"CD000543","volume":"4","author":"Y Wang","year":"2016","unstructured":"Wang Y, Parker CE, Bhanji T, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543.","journal-title":"Cochrane Database Syst Rev"},{"key":"985_CR20","first-page":"000544","volume":"5","author":"Y Wang","year":"2016","unstructured":"Wang Y, Parker CE, Feagan BG, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;5:000544.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-00985-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-019-00985-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-00985-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T03:46:39Z","timestamp":1663386399000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-019-00985-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["985"],"URL":"https:\/\/doi.org\/10.1007\/s12328-019-00985-9","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2019,4,29]]},"assertion":[{"value":"21 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors state that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}},{"value":"Informed consent was obtained from all the patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}